Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Gene may accelerate memory loss in Alzheimer's disease

08 May 2017

By Lone Hørlyck

Appeared in BioNews 899

A gene mutation may speed up memory loss and general cognitive decline in people who are at risk of developing Alzheimer’s disease.

The researchers say that this knowledge could improve the effectiveness of current treatments.

'Because this gene can be detected before the symptoms of Alzheimer’s start, and because this pre-symptomatic phase is thought to be a critical period for treatments that could delay or prevent the disease, it could be a great target for early treatments,' said Dr Ozioma Okonkwo, researcher at the University of Wisconsin School of Medicine and lead author on the study.

Alzheimer’s disease is a neurodegenerative disorder and the most common form of dementia, contributing 60-80 percent of dementia cases. The most prominent symptom is memory loss, particularly for new information, and changes in behaviour.

The study, published in the journal Neurology, followed 1023 healthy, middle-aged people with a heightened risk of Alzheimer’s disease over 13 years. At the beginning of the study, the researchers used blood samples to identify individuals who carried the BDNF Val66Met allele (also referred to as the Met allele). BDNF (brain-derived neurotrophic factor) is a protein that helps neurons survive, grow and specialise.

The researchers evaluated each participant's memory and cognitive skills on up to five occasions. Participants without the Met allele showed slight decreases in verbal learning and memory, while carriers of the Met allele showed greater decreases.

Of the participants, 140 also underwent a scan to assess beta-amyloid plaques in the brain, a hallmark of Alzheimer’s disease. The researchers found that people who both had beta-amyloid plaques and were carriers of the Met allele mutation displayed the most rapid cognitive decline of all groups.

'When there is no mutation, it is possible the BDNF gene and the protein it produces are better able to be protective, thereby preserving memory and thinking skills,' Dr Okonkwo said. He added that previous studies had shown exercise could increase levels of BDNF.

Although the study was one of the largest of its kind, participants were mostly white and Alzheimer’s disease is known to affect ethnic groups differently.

Almost a third of people taking part in the study were carriers of the gene. Dr Doug Brown, Director of Research and Development at Alzheimer’s Society, said:

'These findings should not be cause for alarm, much more research is needed to see whether the results stand up to scrutiny in larger groups of people. However, insights like these could help us better understand what is happening as our brain ages and help to develop new, more personalised, treatments for people with dementia in the future.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

14 August 2017 - by Sarah Gregory 
After the annual Alzheimer's Association International Conference for scientific researchers was held in London this summer, and the subsequent flurry of media interest, the UK dementia charity Alzheimer's Society announced an event for the public to discuss the much asked question: is dementia inherited?...
24 July 2017 - by Caroline Casey 
Two new genes which alter the risk of developing Alzheimer’s disease have been identified...

27 March 2017 - by Julianna Photopoulos 
A genetic test based on 31 markers could be used to predict at what age an individual is likely to develop Alzheimer’s disease...
20 March 2017 - by Dr Julia Hill 
Two common variants of TMEM106B and progranulin (GRN) genes have been discovered to accelerate normal brain ageing...
17 October 2016 - by Annabel Slater 
A new gene therapy has slowed the progress of early Alzheimer's disease in mice...
02 February 2015 - by Dr Victoria Burchell 
A genetic variant may not only help some people live longer, but also changes the way their brain ages, a study suggests....
30 January 2006 - by BioNews 
Gene therapy could help rescue a promising treatment for Parkinson's disease (PD) shelved over safety fears, New Scientist magazine reports. The drug, glial-derived neurotrophic factor (GDNF), was withdrawn in September 2004 - just five months after it had been approved for use in patients. The biotech company that made the treatment...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation